BCAL Diagnostics Limited (ASX:BDX) has completed clinical validation of its next-generation BREASTESTplus 2 blood test for the detection of early-stage breast cancer across all breast densities, with a commercial launch planned for November 2026 commencing in Sydney, Melbourne, and Brisbane ahead of a national rollout.
Key Points
- BREASTESTplus 2 clinical validation completed for all breast densities, validated for women aged 30 years and over.
- In the clinical validation study, the test demonstrated sensitivity of 80.3% and specificity of 48.5% for the detection of early-stage breast cancer (Stage 0 to Stage 2).
- Of the breast cancers detected in the validation study, 61.9% were Stage 0 or Stage 1.
- Commercial launch on track for November 2026, with simultaneous rollout across Sydney, Melbourne, and Brisbane ahead of a national rollout.
- BCAL will attend the 2nd Australasian International Breast Congress in Brisbane from 8–10 October 2026 to build awareness ahead of launch.
Clinical Validation Results and Test Design
The clinical validation study for BREASTESTplus 2 assessed the test's performance for the detection of early-stage breast cancer, covering Stage 0 (DCIS), Stage 1, and Stage 2. The test demonstrated sensitivity of 80.3% and specificity of 48.5% in this study. BREASTESTplus 2 uses an enhanced lipid biomarker panel with stability and reproducibility supported through analytical validation. The test is described as a non-invasive blood test designed to be used alongside other diagnostic pathways. A 'Normal' result supports reassurance, while an 'Elevated' result is described as an early flag that further investigation is warranted. The filing states the test is not intended to diagnose breast cancer as a standalone test.
Independent Bioinformatics Validation and Clinical Input
BCAL worked with OmniOmics.ai, which provided independent bioinformatics validation of BREASTESTplus 2 throughout development. OmniOmics.ai CEO and Founder Dr Fatemeh Vafaee stated the team developed a multifactorial diagnostic algorithm integrating lipid biomarkers measured in plasma with clinical features, and rigorously evaluated the locked algorithm on an independent clinical validation dataset. Clinical input during product development was provided by Dr David Speakman, described in the filing as Breast and Melanoma Surgeon, Clinical Director of BreastScreen Victoria, and Director of Parkville Breast Service. Associate Professor Sanjay Warrier, Consultant Breast Surgeon at Chris O'Brien Lifehouse and Chief Surgeon at BreastScreen NSW, also provided commentary included in the filing.
Commercial Launch Plans and Registry Initiative
BCAL disclosed it is advancing accreditation and commercialisation activities ahead of the planned November 2026 launch of BREASTESTplus 2, with simultaneous rollout across Melbourne, Sydney, and Brisbane preceding a national rollout. Women receiving BREASTESTplus 2 through participating sites will be offered the opportunity to join the BREASTEST Registry, with the collected data to be used to develop real-world evidence for the test. The filing states existing referral pathways, including Best Practice, Genie, and Medical Director, will be updated to incorporate BREASTESTplus 2. The filing noted that approximately only 48% of all eligible Australian women are currently being evaluated regularly with mammogram.



Please wait processing your request...